ResearchMoz.us

ResearchMoz is the one stop online destination to find and buy market research reports. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. We provide the market context, competitor insight and future trends needed for strategic planning. For More Information Kindly Contact: +1-518-618-1030 or Email: sales@researchmoz.us

Friday 31 May 2013

Global Pulmonary Arterial Hypertension (PAH) Therapeutics Market 2012-2018 | ResearchMoz.us

ResearchMoz.us include new market research report" Pulmonary Arterial Hypertension (PAH) Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2012 - 2018" to its huge collection of research reports.

Pulmonary arterial hypertension (PAH), a type of pulmonary hypertension results from high blood pressure associated with arteries of the lungs. In PAH, the arteries of the lungs (pulmonary arteries) become narrower than their actual size, giving rise to high blood pressure in the arteries of the lungs thus putting pressure on the right ventricle of the heart. Some of the main causes of occurrences of this disease are bad habits such as stressful lifestyle, intake of certain medicines etc. There is no exact treatment available for PAH but existing medication may help treat the symptoms. Moreover, if not treated in time the condition may worsen, because continuously straining the pulmonary arteries will put strain on the heart’s functioning and can be life threatening.     
     
The global PAH market is set to grow at a healthy growth rate due to increasing number of patients identified with PAH, increased competition among existing products, advancement in treatment options and more efficacious therapies.  Some of the major drugs available for the treatment of PAH include Letairis (ambrisentan), Adcirca (tadalafil), Tracleer (bosentan), Ventavis (iloprost), Tyvaso (inhaled treprostinil), Remodulin (treprostinil), Veletri (epoprostenol) and Revatio (sildenafil). Revatio, Remodulin and Letairis/Volibris were some of the leading drugs in some of the major geographies such as the U.S., Spain, U.K., France, Germany, Italy, and Japan.  The PAH market is segmented on the basis of mechanism of action which includes platelet aggregation inhibitors, serotonin pathway antagonists, angiotensin receptor antagonists, endothelin receptor antagonists, PDE5 inhibitors, phosphodiesterase inhibitors, P2Y 12 receptor inhibitors, nitric oxide synthetase inhibitors and prostacyclin (PGI2) agonists.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics
It provides a forward looking perspective on different factors driving or restraining market growth 
It provides a technological growth map over time to understand the industry growth rate
It provides a seven-year forecast assessed on the basis of how the market is predicted to grow 
It helps in understanding the key product segments and their future
It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments 
It provides distinctive graphics and exemplified SWOT analysis of major market segments 

For More Information Kindly Contact: 
Email: sales@researchmoz.us

0 comments:

Post a Comment